HC Wainwright reaffirmed their buy rating on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a research report report published on Friday, Benzinga reports. They currently have a $21.00 price target on the stock.
Nuvectis Pharma Price Performance
NASDAQ:NVCT opened at $14.50 on Friday. The business has a 50 day moving average of $14.50 and a 200 day moving average of $14.80. The company has a market capitalization of $249.85 million, a price-to-earnings ratio of -9.35 and a beta of 0.09. Nuvectis Pharma has a 1-year low of $6.21 and a 1-year high of $18.65.
Insider Buying and Selling
In related news, major shareholder Marlio Charles Mosseri acquired 2,584 shares of the stock in a transaction on Friday, July 28th. The stock was purchased at an average price of $13.91 per share, for a total transaction of $35,943.44. Following the completion of the transaction, the insider now owns 2,594,140 shares of the company’s stock, valued at approximately $36,084,487.40. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders bought 146,817 shares of company stock worth $2,410,305 in the last quarter. 38.85% of the stock is owned by insiders.
Institutional Trading of Nuvectis Pharma
About Nuvectis Pharma
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases.
- Five stocks we like better than Nuvectis Pharma
- What Are the FAANG Stocks and Are They Good Investments?
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Use Stock Screeners to Find Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Investing In Preferred Stock vs. Common Stock
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.